Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer
In this video, Vandana Abramson, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, discusses the various strategies utilized in the treatment of metastatic breast cancer. Dr Abramson says that they are looking at new mutations within the subgroups, specificallyPI3 kinase mutations, as targets for estrogen receptor positive breast cancer. For HER-2 positive breast cancer there are many new therapies such as, ado-trastuzumab emtansine, pertuzumab, trastuzumab and more. "That's where I really think breast cancer is headed, said Dr Abramson. "We are figuring out how we can target specific subtypes in a better way."
This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.
If anyone thought Myriad Genetics’ legal battles were over when it lost at the US Supreme Court in 2013, that person would be wrong. In many ways, the ruling in Association for Molecular Pathology v. Myriad Genetics, which found that a naturally occurring DNA sequence cannot be patented, was just the beginning for the Salt Lake City-based testing company.